Clinical trial
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
NCT02972658 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT02972658 |
|---|---|
| Title | A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia |
| Official title | A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study) |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Lanabecestat |
| Enrollment | 421 |
| Start date | Mar 15, 2017 |
| Primary completion | Oct 2, 2018 |
| Completion | Oct 2, 2018 |
| First posted | Nov 23, 2016 |
| Last update posted | Dec 3, 2019 |
| Countries | Australia, Belgium, Canada, France, Germany, Hungary, Japan, Poland, Puerto Rico, Romania, South Korea, Spain and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: